Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use-result survey of GOBIK Aqueous Suspension Syringes
jRCT2061240030Recruiting
- Sponsor
- Research Foundation for Microbial Diseases of Osaka University
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of MT-2355 in pertussis, diphtheria, Tetanus and 2 more, sponsored by Research Foundation for Microbial Diseases of Osaka University. Primary endpoints: Rate of vaccine-related adverse event, Factors that may influence safety and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
MT-2355
03
Conditions
pertussisdiphtheriaTetanuspoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on jRCT2061240030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240030.